The cell fusion of two Ig producing cell lines may result in the codominant expression of all of the parental cell derived Ig chains. For a cell making two Ig heavy chains and two Ig light chains a random association of all chains results in 10 possible configurations of secreted antibody species. In practice, not all the combinations of chains are observed at the predicted frequencies for a random association but the mixture is still usually complex. The interest in these antibodies for therapy stems from the biological properties of different species within the complex mixture. In addition to the properties which depend upon the interaction of different Ig isotypes with human effector mechanisms, there are unique properties which result from the different binding specificities for antigen. For example, certain species of antibody are monovalent for binding to a given antigen. Such monovalent antibodies with specificities for modulating cell surface antigens seem to be more efficient than the equivalent bivalent antibodies at lysing target cells with complement. Another of the components of the mixture has dual specificity for the two different antigens recognised by the parental antibody types. These bi-specific antibodies are capable of targetting drugs or toxins to cells expressing appropriate cell surface antigens. Also of interest is the ability of these bi-specific antibodies to induce very potent tumour cell killing by activated T-cell blasts when the bispecific antibody is used to crosslink a component of the T-cell receptor complex and a suitable cell surface antigen on the target cell. The results of the Third International Workshop and Conference on Human Leucocyte Differentiation Antigens will be presented. There are now a total of 50 named leucocyte differentiation antigens. They have been defined by exchange of monoclonal antibodies followed by comparisons of binding, tissue staining, immunoprecipitation and functional studies. For Immunotherapy has been used to treat pathogens and to provide passive immunity. However, there can be problems, i.e., the 'neutralising' antibody is only a small fraction of the total immunoglobulin, human antisera may be infected with viruses such as AIDS and hepatitis, and antibodies from animal sources are recognised as foreign. These problems should not occur if human monoclonal antibodies are used. Unfortunately, the productron of human monoclonal antibodies has proved difficult. Therefore, we have attempted, via recombinant DNA technology to turn mouse or rat monoclonal antibodies into 'human' antibodies.
At its simplest, variable regions from mouse or rat antibodies conferring the antigen specificity can be combined with human constant domains, resulting in a chimeric antibody having predetermined specificity and effector function (Neuberger et al. Nature, 314: 268, 1985) . Although such antibodies may yet prove to be therapeutically useful, an immune response of the recipient to mouse or rat variable regions seems probable. Therefore the parts of the animal variable domain conferring the antigen specificity have been transplanted into the framework regions of a human variable domain. We have applied this technique to construct 'humanised' antibodies binding a small hapten (Jones et al. Nature, 321: 522, 1986 ) to lysozyme (unpublished) and to a cell surface antigen, CAMPATH I (unpublished).
permit cost effective screening of an apparently healthy population. In order to develop a more specific screening, multiple serum markers have been assayed with a panel of sera from 51 ovarian cancer patients and from 50 individuals with benign disease whose serum CA-125 levels exceeded 35 U ml-t. Among the patients with ovarian cancer, elevations of CA-125 (>65Uml -1) were observed in 63 %, CA15-3 (>3OUml-1) in 590o, TAG 72.3 (>lOUml1-) in 470, placental alkaline phosphatase (PLAP) in 310%, HMFG1 in 76%, HMFG2 in 63% and NB/70K in 57%. All patients with elevated CA-15-3 or TAG 72.3 also had a CA-125 >35Uml-I. Among the 50 'false positive' sera selected from 4,947 donors, CA-125 was >35% in 100%, NB/70K was elevated in 62%, TAG 72.3 in 6% and CA-15-3 in 2%. PLAP also appeared quite promising in that elevated enzyme levels were not found in the 'false positive' group. HMFG1 was elevated in 26% and HMFG2 in 12%. Among ovarian cancer patients with CA-125 >65Uml-1, TAG 72.3 or CA-15-3 was elevated in 83%. In the 'false positive' group, only 5% of patients had elevations of one or other marker. Prospective studies are required to test whether serum markers in combination will prove sufficiently specific to justify their use in individuals at risk for ovarian cancer.
Radiolabelled monoclonal anti-CEA antibodies and fragments in colon carcinoma -diagnostic and therapeutic approach Thirty-one patients with known colo-rectal carcinoma were injected with 1-123 labelled F(ab')2 or Fab (n = 17) fragments from monoclonal antibodies (MAb) anti-CEA. Patients were examined by ECT at 6, 24 and sometimes 48 h after injection using a rotating dual head scintillation camera. As recently reported (Delaloye et al., J. Clin. Invest, 77, 301, 1986) , all 23 primary tumours and local recurrences except one were clearly visualised on at least two sections of different tomographic planes. Interestingly, 9 of these patients had almost normal circulating CEA levels and 3 of the visualised tumours weigh only 3 to 5 g. Following encouraging preliminary results of tumour therapy in nude mice, showing that anti-CEA MAbs labelled with therapeutic doses of 1-131 could inhibit the growth of human colon carcinoma xenografts or provoke tumour regression. Seven patients with liver metastases of colon carcinoma were injected into the hepatic artery with MAbs anti-CEA labelled with 100 mCi 1-131. We observed no side effects and good localisation of Immunocytochemistry has now established itself as a valuable procedure in surgical pathology. A variety of antibodies, both polyclonal and monoclonal are in use, and they are usually well characterised and commercially available. The illustrated examples are arbitrarily grouped into lymphoreticular markers, cell membrane antigens such as HMFG1 and 2, cytoskeletal components (intermediate filaments and actin), enzymes (NSE, prostatic acid phosphatase, PLAP), cytoplasmic protein (e.g. S-100), extracellular base membrane components (collagen type 4 and laminin), 'appropriate' cell products (peptide hormones, thyroglobulin, myoglobin, factor VIII-related antigen) and 'inappropriate' products including 'tumour markers' (CEA, AFP, HCG hormones The ability to monitor cellular events and to identify, morphologically, sub-cellular components involved in particular processes has greatly advanced since the advent of monoclonal antibodies and their use in electron immunocytochemistry. For instance, using simultaneous monoclonal and polyclonal antibodies (to proteins and enzymes capable of monitoring intracellular pH) on specially prepared tissues it is now possible to visualise intracellular pathways involved in protein synthesis.
The demonstration of co-existence of several substances (e.g., active peptides) in a single cell has been greatly aided by the use of monoclonal and polyclonal antibodies in combination. For light microscopical studies, different reaction products are revealed by the use of differently coloured chromagens. For electron microscopy, monoclonal and polyclonal antibodies are labelled with gold particles of different sizes and are used on ultra-thin sections (the ongrid immunolabelling or post-embedding method).
Low numbers of binding sites on cellular membranes can now be visualised at the electron microscopical level, by the use of specific monoclonal antibodies to receptors or by the construction of divalent forms of antigens that can react with the receptor and subsequently to a monoclonal antibody. Again, the reaction is revealed by gold labelling procedures.
Results of 1st international workshop on small cell lung cancer antigens The workshop used methods, developed in three international workshops on leucocyte differentiation antigens, to group together clusters of monoclonal antibodies (mAbs) with similar reactivity. Antibodies submitted to the workshop were coded and sent to participating laboratories which were requested to carry out immunohistological, immunocytochemical or FACS analysis on a range of tissues or cell lines. Data from these studies was used to perform a computerised cluster analysis. The results show that methods developed by FACS analysis of mAbs to leucocyte antigens can be applied to solid tumours. We have detected a cluster of 12 mAbs reacting with SCLC which also reacts with neuronal cells. Other smaller clusters of mAbs have also been detected. The method provides a basis for identifying and classifying antigens of any cell type and allows comparisons of different antibodies to be made in an unbiased fashion. In relation to small cell carcinoma of the lung, it has identified mAbs which have sufficient specificity to be useful in the classification of lung tumours and might have a future role in diagnosis or therapy. The specific uptake of 125-I-A6H antibody by xenografts of the RCC in the athymic mouse was considerably greater than that seen for other human tumour xenografts and their associated antibodies. The A6H-RCC model also demonstrated both greater localisation indices and absolute amount of antibody bound than did the B6.2-Clouser model. Several physiological factors were studied to assess whether they might play a role in this greater specific uptake. VP was determined by measuring the amount of 125-I-BSA and 131-I nonspecific IgCl extravasated out of the vasculature during one hour. BF to the tumour was determined using the 86-Rb method. BF and VP were found to be greater in the RCC xenografts than in CL tumours. Differences in VP were dramatic, showing the vasculature of the RCC xenograft was twice as permeable as that of the CL tumour. Animals bearing RCC or CL xenografts were injected with a monoclonal antibody to human major histocompatibility complex (125-I-anti-HLA). Tumour uptake of 125-I-anti-HLA was found to be 5 x greater in RCC than CL xenografts. These results, therefore, suggest that the differences seen in the physiological factors can account for some of the greater specific 125-I-A6H uptake by the RCC. We have evaluated a new technique for labelling platelets using In-lI-labelled monoclonal, IgGI, antibody (P256) raised against the platelet surface glycoprotein, GlIblIla (Imperial Cancer Research Fund, London). P256 was labelled by coupling to DTPA followed by chelation of In-111. In-111 uptake was 5-7 mCi mg -1 P256. Platelet function following exposure to P256 was tested by measurement of spontaneous aggregation and aggregometry using a whole-blood platelet counter (Ultra-flow 199). A platelet receptor occupancy of 6% was the maximum that resulted in spontaneous aggregation in platelet-rich plasma (PRP), comparable to that seen in the absence of P256. The antibody can be shown to label platelets both in vitro and in vivo. The FAB/2 fragment of P256 has also been shown to label platelets in vitro. One normal volunteer and 12 patients with suspected venous thrombus have been imaged with either Indium-l 1 labelled P256 or its fragment. Localisation in thrombus was seen in 5. This technique therefore promises to be a simple specific method of platelet labelling. We have evaluated 2 different 1-131 labelled IgM human monoclonal antibodies (HMoAb) for their ability to image tumours and their pharmacokinetics when given in escalating doses in I I pts with metastatic colon cancer. Seven pts received 5 mCi and 8-108 mg of HMoAb 28A32 obtained from a human-mouse hetero-hybridoma, and 4 pts received 5 mCi and 8-58 mg of HMoAb 16.88 obtained from a transformed human lymphocyte. Both HMoAb react with a colon carcinoma associated antigen. All pts had positive immunohistology in a previously resected tumour biopsy. The antibodies were labelled via the iodogen method at a mean specific activity of 1. mCi mg -with good retention of immunoreactivity. All pts underwent an initial study with 8 mg of HMoAb followed by a second study at the higher HMoAb dose 7 days later. Imaging was seen in 6/7 pts receiving 28A32 and in 3/4 pts receiving 16.88. Initially tumours appeared as 'cold' lesions with optimal contrast between tumour and non-tumour after 5 days that persisted up to 23 days. There was 29-38% of the dose in plasma at 24 h and a whole body clearance (T 1/2) of 1.5 days. No dose dependent differences were observed in the pharmacokinetics or tumour imaging. One One thousand and ten apparently healthy postmenopausal female volunteers over 45 years of age and with a history of amenorrhoea for greater than 12 months attended for venopuncture and pelvic examination. Serum samples were assayed using the Abbott Laboratories CA-125 radioimmunoassay kit. The 90th, 95th and 98th centiles for serum CA-125 in this group of postmenopausal women were 23.2, 26.3 and 30.85 U ml-respectively. Thirty-one women with CA-125 level >30 U ml-1 proceeded to ultrasound scanning. Three of these women underwent surgery following an abnormal ultrasound scan of which 1 had no abnormality, 1 a fimbrial cyst and the third a stage I B ovarian cancer. The other 28 had no abnormality on ultrasound scan and have been followed up with 3 monthly serum CA-125 measurement and repeat scans. In addition, 7 benign tumours found on vaginal examination and confirmed by ultrasound scans were removed at laparotomy. None of these 7 women had a serum CA-125 > 30 U ml -1.
We conclude that CA-125 has high specificity for ovarian cancer when used to screen postmenopausal women. To achieve maximal sensitivity the upper normal limit for serum CA-125 in a screening programme for ovarian cancer incorporating the CA-125 assay and ultrasound scanning should be set at 23 U ml-1. This would result in -10% of the screened population requiring an ultrasound scan. The value of the CA-125 assay for early diagnosis of ovarian cancer warrants further investigation in a randomised controlled study.
A phase I study using pan T lymphocyte-ricin A chain immunotoxin to treat steroid resistant graft versus host disease (GVHD) A phase I clinical trial has been completed in which bone marrow transplant recipients with grade II-IV steroid resistant GVHD were treated with an immunotoxin constructed by linking monoclonal antibody XMMLY-H65, directed against the CD5 antigen on human lymphocytes, to ricin A chain . Patients received up to 14 daily infusions of XMMLY-H65 in escalating doses. To date, more than 14 evaluable patients have been accrued. The treatment was well tolerated without noticeable toxicity.
The most consistent finding was a rapid drop in T-lymphocytes, which usually persisted throughout the course of infusions. Target tissue clearing was seen early with skin, during the first 2-5 days of infusion, and later with gut, within the first week after completion of infusions. Peripheral T-cells reappeared 1-3 weeks after treatment, without recurrence of GVHD. Anti-immunotoxin antibodies were present in some patients. We conclude that immunotoxin treatment represents a promising therapy for patients with severe acute or chronic GVHD. In radioimmunotherapy (RIT), antitumour antibodies are used to deliver 1-131 specifically to the tumour. For the effects of RIT to be clearly understood, it is necessary to quantify the concentrations of the radionuclide in various organs. Planar gamma camera imaging has been used in previous studies but this leads to problems where there are overlying organs or tissue. SPECT overcomes these problems by providing a 3-dimensional representation of the activity distribution. Planar imaging and SPECT were compared in phantom studies and in patients receiving therapeutic doses of 1-131-labelled anti-CEA. The method of Thomas et al. (Radiol., 133, 465, 1979) was used for quantitation. From the planar images for SPECT, back projection reconstruction was used with attenuation correction. Scattered photons were compensated for using data acquired simultaneously from a secondary window. All data were obtained on an IGE Gemini 700 gamma camera with a high resolution 400 KeV collimator. The limitations of SPECT quantitation were examined using phantom studies and it was shown that practical SPECT quantitation can be achieved in patients given therapeutic doses of 1-131-labelled anti-CEA. This is likely to be of value in dosimetry for RIT and other treatments using 1-131. In vitro binding assay on tumour homogenates with 131-Ispecific and 125-I non-specific MCA show high 'dose delivery' and specificity. However, i.v. injections produce scintigraphic tumour images but result in low specificity and indices and <0.005% injected dose delivered to tumour.
In contrast, administration of labelled MCA into CSF pathways produces more specific tumour binding. Biological responses and increased survival (1-2 years) were seen in 5/7 patients given antibody-guided therapy (11-50 mCi-131-I) for neoplastic meningitis from medulloblastoma, lymphoma, melanoma and pineoblastoma. All cases had relapsed after optimum conventional therapy. No significant side effects occurred. This approach may offer an alternative to the prophylactic external beam radiation which is used to achieve CSF 'clean up' in certain paediatric malignancies but has adverse effects on CNS development. Both patients and healthy controls have low serum levels of IgM antibody rheumatoid factors which react with both human and murine IgGI. These rheumatoid factors cause the pre-existing human anti-mouse response.
After one therapeutic administrstion of murine antibodies, patients develop antibodies which react with the Fc portion of the murine immunoglobulin. Subsequent administrations lead to the generation of both anti Fc and anti F(ab')2 antibodies. A component of the anti-F(ab')2 response is antiparatopic. These anti-paratopic or anti-idiotypic antibodies (anti-id) reflect the internal image of tumour associated antigens and in in vitro assays, block the binding of the administered murine antibody to its antigen.
In those patients with anti-id' antibodies, antibodies with binding specificities similar to the administered murine antibodies are detectable. These are anti-id2 or anti-tumour antibodies generated by either an anti-idiotypic network or by elevated circulating antigen. In the perspective of therapeutic in vivo targetting for T-cell attack, the monoclonal antibody (MAB) MOvI8, selected for its restricted reactivity with human ovarian carcinoma and an anti-T3 MAB, were used to produce heteroconjugates or hybrid antibodies derived by the fusion of the relevant hybridomas. The specificity and the activity of the bispecific MABs were analysed by solid-phase RIA, immunofluorescence, competitive binding and a 51-Cr release assay on the ovarian carcinoma cell line OVCA432 which expresses the relevant tumour-associated antigen and on several irrelevant tumour cell lines and normal cells. Both reagents efficiently promoted, at nanomolar concentration, target cell lysis by cytotoxic T-cell (CTL) clones. Although the pattern of the tumour cell lines which were lysed was wider than that predicted by the binding studies, further studies using a more sensitive biochemical technique confirmed that the specificity of the MABs is superior to heteroaggregates both in purification recovery and storage stability. Peripheral blood lymphocytes could also be used as cytolytic effectors, provided that a suitable in vitro activation scheme was adopted.
Tumour therapy with vinca alkaloids targetted by a hybrid-hybrid monoclonal antibody recognising both CEA and vinca alkaloids puting an index of antigenic expression which took into account the percentage of stained cells and the intensity of staining. For the 3 antibodies, this index was respectively 166, 114 and 73. Nude mice were injected i.p. with 2 x 107 cells, and the peritoneal cavity became progressively lined by tumour nodules before the animals died at 80+5 days. The first biodistribution studies were performed with In-Il 1-DTPA-OC125 antibody (In-OC125) injected i.p. in intact form 50-60 days after i.p. grafting of the tumour cells. The animals were sacrificed 2 and 24h after injection (5 mice for each time period), and the results expressed as percentage of injected dose g-1 (% IDg-1) and in tumour-to-organ ratios. A nonspecific immunoglobulin labelled under the same conditions (In-NS) was injected into the same number of mice. With In-OC125 the % IDg-I in the tumour was 14.4+0.7 and 27.8 + 8.6 at 2 and 24 h respectively; with In-NS the percentage for the same time periods was 8.9+1.7 and 4.4+0.8. With In-OC125 the tumour/blood, tumour/liver and tumour/kidney ratios were respectively 3.7 + 0.8, 4.8+0.9 and 3.7+0.9 at 24h; with In-NS the same ratios were 1.1 +0.3, 1.2+0.7 and 0.7+0.2. These first results are very encouraging and suggest that the same distribution study should be carried out for therapeutic purposes by replacing indium-iII with yttrium-90. Glia fibrillary acidic protein (GFAP) and glioma associated antigens (GAA) defined by monoclonal antibodies (McAbs) were demonstrated simultaneously in human astrocytoma tissue. GFAP was stained by PAP-method, GAA were visualised by ABC-technique using alkaline phosphatase.
Fresh tumour samples from biopsy material were immediately frozen in liquid nitrogen and propagated in tissue culture, respectively. Tumours were grafted to nude mice by inoculation of 5 x 106 cells and cryosections were then taken from primary and secondary tumours. For production of McAbs against GAA, BALB/c mice were immunized with whole glioma cells.
In both primary and secondary tumours, heterogeneity of GFAP-and GAA expression was obvious. While GFAP was restricted mostly to cell processes and less marked in the perinuclear space, McAb-positive material was located either in the tumour cell, surface membrane or cell processes. There was remarkable expression of GAA in cell clusters which failed to express GFAP. At higher magnifications, three types of cellular reactivity were detected; (a) cells reacting only with anti-GFAP, (b) cells reacting only with anti-GAA and (c) cells expressing both GFAP and GAA. Because these cells can be found in s.c. tumour grafts, they may represent not only reactive cells, but also be part of the tumour cell populations. We examined the relationship between tumour proliferation and activation of blood coagulation products. Blood activation results in the formation of fibrin which is degraded by fibrinolysis producing fibrin degradation products (FDP) . Using an ELISA assay with a monoclonal antibody specific for FDP, we studied FDP plasma concentrations in 50 patients with ovarian cancer.
In untreated patients, FDP levels correlated with abdominal tumour size as measured by laparotomy and CA125 assays. In 6/50 patients, however, only the FDP level reflected the abdominal spread and thus was the best marker with which to follow the evolution of these patients. On chemotherapy, two groups of patients were examined comparing FDP levels with those of CA125. In group I (n= 14) FDP levels acted as a tumour marker, since a good correlation was found between the level of FDP and that of CA125 and tumour size. In group 2 (n= 10), FDP levels remained high, despite a significant decrease in CA125 levels and in tumour volume. The ratio FDP/CA125 was at least 5 times higher than the initial ratio. Chemotherapy had a similar toxicity in the 2 groups, but the response evaluated by a second laparotomy was better in the patients of group 2 than in those of group 1 (complete remission was never observed in the 14 patients of group 1, but was observed for 6/10 patients in group 2). Therefore, high levels of FDP in patients on chemotherapy is associated with a better clinical response. We hypothesise that, in group 2 patients, stimulation of monocytes or macrophages by chemotherapy (causing elevated FDP levels), may explain the better response to chemotherapy. CA125 is a common constituent of the glandular epithelium of the female genital tract. The clinical significance of CA125 as a tumour marker in carcinomas of the endocervix, endometrium and fallopian tube was tested by immunohistochemical detection of CA 125 in 54 cancer tissues and by radioimmunometric measurement of CA 125 levels in 12 cancer cytosols and in serum samples of 60 patients with recurrent carcinomas. Positive immunohistochemical staining was present in 80% of the adenocarcinomas. In well differentiated tumours the CA125 antigen was mainly concentrated at the apical poles of the cytoplasms and in the luminal mucus. In poorly differentiated carcinomas a predominantly diffuse cytoplasmic staining was observed. At least 35% of the cancer cells in each tissue section were negative for CA125. In cancer cytosols of the endometrium, the CA 125 levels ranged from 173 to 13,215 U mg -I cell protein. The CA 125 serum concentrations were below the cut-off value of 65 U ml -in 85% of patients with primary cancer and in cases with positive immunohistochemical staining and high cytosol levels. Elevated serum levels were mainly observed in patients with advanced primary cancer (stage III/IV; 30%) and recurrent carcinomas (79%). Apparently, the release of the antigen into the circulation is prevented by a tissue-blood-barrier, which has to be penetrated by a substantial quantity of infiltrative tumour tissue and/or vessel invasion. Therefore CA 125 may be a useful tumour marker only in advanced carcinomas of the endocervix, endometrium and fallopian tube. After iodination, Mabs were tested for their immunoreactivity: they were submitted to an immunoaffinity assay using CEA coupled to Sepharose. The in vivo performances of 3 Mabs recognising different epitopes on the CEA molecule were compared in tumour bearing nude mice. The immunoaffinity assay on CEA-sepharose was found to be a good way to select Mabs suitable for in vivo use. Using a monoclonal antibody-based radioimmunoassay inhibition method, we have determined pre-operative serum levels of the carcinoma associated carbohydrate antigen CA50 in 266 patients with primary colorectal cancer. CA50 levels exceeding the mean value for blood donor sera by more than 2 standard deviations were found in 47% of these patients. 15%, 430, 31% and 65% were elevated in patients with Dukes A, B, C and D respectively. Only 5% of patients with benign colorectal disease had elevated levels and these were patients with ulcerative colitis of a duration of > 10 yr. Among patients who had developed a known recurrence after operation for a primary Dukes' A-C colorectal cancer, 66% had elevated levels, 25% of resected patients with no clinical evidence of disease after operation also had elevated CA50 levels. Two monoclonal anti-MAM6 antibodies, designated 115D8 (IgG2b) and 140C1 (IgGl) have been labelled with Ill-In via DTPA-chelation and assessed for localisation in human ovarian carcinoma xenografts in nude mice.
DTPA was attached to the antibody in varying molar ratios of 4:1, 8:1, 16:1, in order to determine the influence of the DTPA-coupling on the in vivo distribution of the MoAb. Following removal of the free DTPA on a sephadex G25 column, 111-In-tropolonate was added to the DTPAMoAb. Unbound IIl-In was separated from the bound fraction using a sephadex G25 column. The specific radioactivity was kept the same in each study. Tumour bearing nude mice, with comparable tumours, were injected i.p. and imaged at several time intervals. The mice were then dissected and the organs weighed and counted for radioactivity. We found that superior images were obtained when low DTPA:MoAb ratios were used and thus these labelling conditions are recommended for clinical studies. The aim of this study was to assess the biodistribution and therapeutic benefit of 131-iodine labelled Lipiodol in patients with liver tumours.
Patients and methods. 42 patients aged 44-78 years, with liver cirrhosis (10), liver metastasis (13) or HCC (19), were investigated. Two ml of 131-I-labelled Lipiodol (70 MBq) were injected into the hepatic artery via a Seldinger's catheter. Scans were performed over the abdomen and the thorax, 6h after injection and at days 4, 8, and 15. Eight patients with metastasis and 7 with HCC received, 2-4 weeks later, a second injection of 900-1600MBq of 1-131 Lipiodol.
Biodlistribution results: (1) in patients with metastasis and HCC, there was no activity outside the liver and the lungs.
(2) 64% to 91% (median 82%) of the injected dose was taken up by the liver after 6 h. (3) For the HCC, the cpm ratio of tumour to normal liver ranged from 2.4-6 (median 4.6). (4) The slopes of radioactivity decay were identical in the normal liver and the lungs, but smaller in the tumour. (5) The effective half life of 131-I Lipiodol ranged from 3.6-10 days (median 4.6). (6) During an 8 day sampling period, the iodine radioactivity in the urine was 30-50% (median 42%) of the injected dose. (7) Generation of monoclonal antibodies (mAbs) to human gastrointestinal tumours often yields mAbs with carcinoembryonic antigen (CEA) specificity. In an attempt to develop a rapid and reliable strategy for detecting CEA reacting hybridoma-supernatants (HS) at an early stage of the screening process, we tried 3 different approaches: (1) HS were screened by fluorescent immunoassay (FIA) with purified CEA coated onto plastic wells. Forty-eight HS from 2,000 tested, were positive. (2) Fifty-three HS were tested applying soluble, biotinylated CEA. Twenty-two were positive, 5 of which were negative in the solid phase assay. (3) Thirty-eight HS were tested in Western blot assay with nitrocellulose bound CEA after SDS-PAGE. Eleven HS showed a positive reaction, 8 of which had been positive in solid phase FIA and solution based assay, 3 of them only in solid phase assay. These data indicate that >50% of positive results obtained by solid phase immunoassays are false positive when re-examined in solution based assays. Yet the latter system may fail to detect specific antibodies in some cases. These findings suggest that a combination of different assays is necessary to determine antibody specificity. 90-Yttrium has been suggested as a suitable isotope for radioimmunotherapy. This pure beta emitter (max 2.3 MeV, t 1/2=64 h) can be produced from a 90-Sr generator. The monoclonal antibody HMFG1 and its F(ab')2 fragment were coupled to DTPA using the bicyclic anhydride method. The number of DTPA molecules per antibody was estimated and immunoreactivity was tested by ELISA. 90-Y was reacted with each conjugate at pH 6.0, 22 C for 2 h, giving specific activities of 0.8-1.3uCiug-1 (81-91% labelling efficiency). (%IDg-1). The blood activity peaked at 2h (20% IDg-1) for both conjugates with a tl/2 of 39h and 14h for HMFGI and F(ab')2 respectively. Over 3 days, liver, spleen and femur activity increased while lung activity decreased for both conjugates. Liver and femur activity were the same at 3 days (12% IDg -for HMFG1, 10% IDg for F(ab')2). The most significant differences were in kidney levels; 26% IDg-for F(ab')2 by 3 days (20% IDg-1 at 5 days) compared with a constant 6% IDg-1 for intact IgG. Although radioimmunoscintigraphy (RIS) has progressed rapidly over the last few years, tumours < I cm in diameter cannot be diagnosed by RIS due to the limitations of scintigraphic imaging. In an attept to improve this, we developed a hand-held gamma ray detection probe for intraoperative application. With this device it is now possible to scan over the operation area during the surgical procedure. In this way, the probe can be brought into close contact with questionable malignant tissue. This should result in an enhanced sensitivity in the detection of small tumour masses in contrast to conventional RIS. The results achieved so far in a small number of patients (n=6) In an attempt to pre-operatively detect clinical and subclinical axillary lymph node metastases in patients with breast cancer, we used the 131-I-labelled HMFG2 and F(ab')2 HMFG1 monoclonal antibodies. We studied 10 patients with clinically obvious axillary lymph node disease (group A), 10 patients with clinically negative axilla (group B), using 131-I-labelled HMFG2 and 5 patients with clinically negative axilla (group C), using 131-I-labelled F(ab')2 HMFG1. All patients had clinical diagnosis of breast cancer. Each patient received 1-1.5 mCi (specific activity 5 mCi mg -protein) as a s.c. injection into the webs between the 2nd and the 3rd fingers of both hands. The healthy side was used as a control. The patients were scanned at 24 and 48 h after the injection. In group A, 7/10 patients had positive scans. Histology and immunoperoxidase staining confirmed the presence of tumour in the lymph nodes in all patients.
In group B there were 4 true positive scans, 4 true negative, 1 false positive (due to non-specific reaction) and 1 false negative. Histology and immunoperoxidase staining showed lymph node involvement in 5 patients. In group C there were 4 true negative scans and the histology confirmed the absence of tumour in the axillary lymph nodes. In one patient the radiolabelled antibody was arrested in the middle of the right arm probably due to lymphatic obstruction, although no clinically apparent lymphoedema was present.
These The use of monoclonal antibody-drug conjugates to selectively increase the delivery of drug to tumours whilst reducing whole body toxicity is currently being assessed. Targetting studies are currently underway to assess the tumour localisation and whole body biodistribution of the anti-P72,000 dalton glycoprotein monoclonal antibody 791T/36 conjugated to cytotoxic drugs including methotrexate (MTX) and a plant-derived toxin.
Preliminary studies in mice with human tumour xenografts have demonstrated the preferential localisation of radiolabelled immunoconjugates. Tumour localisation of the immunotoxin preparations has not been visualised and accumulation of the toxin by the liver appears to be the main problem although a therapeutic effect has been observed in the mouse xenograft model. Clinical imaging studies in 15 patients with colorectal cancer injected with 70MBq 1-131-labelled 791T/36-methotrexate (200, ug antibody: 1.6, ug MTX) have demonstrated that the biodistribution of the drug-conjugate is similar to that of the unconjugated antibody. A T:NT uptake ratio of 2.9:1 has been measured from resected specimens. However, an assay is being developed to determine the concentration of drug in tumour and normal tissues.
Further clinical studies will be necessary to assess the targetting ability of antibody-drug conjugates prior to their use for tumour therapy. Biologically targetted radiotherapy (BTR) with radiolabelled antibodies or biochemical molecules such as MIBG has the potential to improve the treatment of neoplastic disease. The area where there is the greatest theoretical promise is in the treatment of systemic disease where surgery or local radiotherapy are not applicable. In common with other forms of radiation therapy, the factor determining allowable radionuclide doses will be the capacity of normal organs to withstand radiation insult. Current Mathematical model studies indicate that combination TBI/BTR schedules incorporating BMR may be the optimal strategy for treatment of systemic malignancy using these radioisotopes. We are using an l-131 labelled cocktail of mg anti-CEA and OC 125 F(ab')2 fragments with a total activity of 80-120 MBq (IMACIS 2/CIS-Isotope Diagnostic).
We investigated 30 patients after primary treatment of ovarian cancer and 8 women preoperatively. Scanning was done 1-7 days after application of the cocktail with SPECT and planar technique. RIS was proven by CAT-Scan and surgical means. We calculated the tumour to nontumour tissue ratio (T/N) scintigraphy at the 6th day p.i.
In the follow-up 21 of 30 women had a relapse and/or metastasis in the true pelvis. Eighteen had a true positive scan. The T/N ratio was 1.6 and 2.2 (mean 1.8). Two patients had a false positive scan, one proven pathologically (Figo stage 3, RIS and biopsy after second look and chemotherapy). Three scans were false negative, T/N ratio 1.3; 1.3; 1.4.
In 16 patients metastatic disease was found outside the true pelvis. In 13 we found a true positive scan. The T/N ratio was between 1.8 and 2.8 (mean 2.0). Three scans were false negative (lung/liver/liver). Eight scans were false positive: increased liver uptake (3), cyst in the liver (1), ascites (1), increased paraaortic uptake (lymphnodes) (3) CAT-scan: no disease.
RIS is a useful diagnostic tool in the follow-up management of ovarian cancer; nevertheless the T/N ratio is low. Bone marrow aspirates from 45 patients and trephine biopsies from 18 patients were taken at the time of primary breast cancer therapy (stage TI-3, NO-2, MO-1). All patients were screened for distant metastasis (X-ray, bonescan).
Tumour cells in the bone marrow aspirates were detected by immunohistochemistry using monoclonal antibodies against EMA (epithelial membrane antigen) and LICR-LON-M8 (kindly provided by the Ludwig-Institute, Sutton, UK).
In 15/45 patients, bone marrow aspirate staining of tumour cells (6-32 cells) could be demonstrated. Four of the 15 patients were at stage I, 9 at stage II, one at stage III and one at stage IV disease at the time of clinical presentation. In the 18 trephine biopsies, tumour spread could not be detected. The median follow-up time was 13.1 months (min. 3 months, max. 27) .
Eight of the 15 EMA-positive patients developed bone metastases and also had visceral involvement. Two out of the 30 EMA-negative patients developed local recurrence, one visceral metastasis, and one bone metastasis. The median time from bone marrow sampling to metastasis in EMApositive patients was 6.5 months. To detect the overall survival rate longer follow-up periods and greater patient numbers are required.
We conclude that bone marrow sampling can detect bone micrometastasis at the time of primary therapy.
